S. Z. Safina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. Z. Safina has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Alexey S. Kalpinskiy
P. A. Hertsen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia
3 shared publications - Andrey A. Lebedinets
Leningrad Regional Clinical Hospital
3 shared publications - Ilya Tsimafeyeu
Bureau for Cancer Research - BUCARE, New York, NY 10032, USA
3 shared publications - Vladislav V. Petkau
Sverdlovsk Regional Oncological Dispensary; Ural State Medical University
3 shared publications - Aleksei Shkurat
Leningrad Regional Clinical Hospital
2 shared publications - Anastasiya S. Mochalova
Petrovsky National Research Center of Surgery, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
Analysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.
- 4 March 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
Open AccessAnalysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.
- Open Access
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Efficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.
- 6 August 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 25-32
Open AccessEfficacy of avelumab and axitinib depending on disease burden in patients with metastatic renal cell carcinoma: a subgroup analysis of the RAVE-Renal trial
Background. Immunotherapies and targeted therapies have demonstrated significant efficacy in prospective randomized trials establishing them as the standard of care for patients with metastatic renal cell carcinoma.This analysis, part of the RAVE-Renal real-world study, aimed to evaluate the effectiveness of avelumab plus axitinib based on disease burden and the presence of liver and bone metastases.Materials and methods. The RAVE-Renal trial was a multicenter, ambispective study that included treatment-naïve patients with histologically confirmed metastatic renal cell carcinoma and measurable lesions. Patients were treated with avelumab (800 mg every two weeks) and axitinib (5 mg twice daily). Primary endpoints were median progressionfree survival (PFS) and objective response rate (ORR). Secondary endpoints included median overall survival, 1-year overall survival, and safety. Subgroup analyses evaluated median PFS and ORR in patients with ³2 organ metastases, bone metastases, and liver metastases.Results. A total of 125 patients from 13 centers were enrolled, with median follow-up of 16.1 months and median age of 61 years. Based on IMDC (International Metastatic RCC Database Consortium) risk categories, 35.3 % had favorable, 49 % had intermediate, and 15.7 % had poor prognosis. The overall population demonstrated median PFS of 14.9 months and ORR of 44.3 %. Among patients with ³2 organ metastases, median PFS was 13.0 months, and ORR was 36.7 % (all p 0.05). In those with bone metastases, median PFS was 6.5 months (p = 0.160), and ORR was 23.5 % (p = 0.0148). For patients with liver metastases, median PFS was 17.6 months, and ORR was 45.5 % (all p 0.05).Conclusion. The combination of avelumab and axitinib demonstrated consistent efficacy in patients with advanced disease including those with liver and bone metastases. These findings suggest the regimen’s broad applicability and suitability in real-world clinical practice.
- 3 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 7-16
Results of an international, double-blind, randomized, phase III clinical trial to compare the efficacy and safety of a biosimilar pertuzumab (BCD-178) with reference pertuzumab in patients with HER2-positive breast cancer
Introduction. The increasing need for affordable treatment options for patients with HER2-positive breast cancer necessitates the development of pertuzumab biosimilars to expand access to effective therapies. BCD-178 is a pertuzumab biosimilar that has demonstrated equivalence to reference pertuzumab (RP) based on physicochemical characterization, preclinical in vitro and in vivo and clinical phase I study. The international, multicenter, Phase III clinical trial BCD-178–2/PREFER was conducted to comparatively evaluate the efficacy and safety of BCD-178 and RP in combination with TCHP regimen for neoadjuvant therapy in patients with HER2-positive breast cancer.Objective. To compare the efficacy and safety of the pertuzumab biosimilar BCD-178 and RP when used in a neoadjuvant setting for patients with HER2-positive breast cancer.Methods. The study included female patients aged 18–75 years with histologically confirmed invasive HER2-positive breast cancer and the absence of estrogen receptor (ER) and progesterone receptor (PR) expression. Patients were randomized 1:1 to receive either BCD-178 or RP. The primary endpoint was the proportion of patients achieving a total pathological complete response – tpCR (ypT0/is, ypN 0) based on the conclusion of a central independent review after completion of the neoadjuvant therapy phase.Results. A total of 380 patients were randomized into the study. The proportions of patients achieving tpCR (95 % CI) were not statistically different between the treatment groups (p=0.6521, Cochran–Mantel–Haenszel method). The risk difference (95 % CI) for achieving tpCR between the groups was within the pre-defined equivalence boundaries, demonstrating equivalent efficacy of BCD-178 and RP. The treatment groups were comparable in terms of safety profile, including the incidence of adverse reactions (ARs). The most common (≥10 % of patients) ARs were diarrhea and anemia. The pharmacokinetics and immunogenicity of the drugs were comparable.Conclusions. The study demonstrated comparability between BCD-178 and RP in terms of efficacy, safety, pharmacokinetics, and immunogenicity when used in the neoadjuvant treatment of patients with HER2-positive ER/PR-negative breast cancer.
- 3 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 7-16
Results of an international, double-blind, randomized, phase III clinical trial to compare the efficacy and safety of a biosimilar pertuzumab (BCD-178) with reference pertuzumab in patients with HER2-positive breast cancer
Introduction. The increasing need for affordable treatment options for patients with HER2-positive breast cancer necessitates the development of pertuzumab biosimilars to expand access to effective therapies. BCD-178 is a pertuzumab biosimilar that has demonstrated equivalence to reference pertuzumab (RP) based on physicochemical characterization, preclinical in vitro and in vivo and clinical phase I study. The international, multicenter, Phase III clinical trial BCD-178–2/PREFER was conducted to comparatively evaluate the efficacy and safety of BCD-178 and RP in combination with TCHP regimen for neoadjuvant therapy in patients with HER2-positive breast cancer.Objective. To compare the efficacy and safety of the pertuzumab biosimilar BCD-178 and RP when used in a neoadjuvant setting for patients with HER2-positive breast cancer.Methods. The study included female patients aged 18–75 years with histologically confirmed invasive HER2-positive breast cancer and the absence of estrogen receptor (ER) and progesterone receptor (PR) expression. Patients were randomized 1:1 to receive either BCD-178 or RP. The primary endpoint was the proportion of patients achieving a total pathological complete response – tpCR (ypT0/is, ypN 0) based on the conclusion of a central independent review after completion of the neoadjuvant therapy phase.Results. A total of 380 patients were randomized into the study. The proportions of patients achieving tpCR (95 % CI) were not statistically different between the treatment groups (p=0.6521, Cochran–Mantel–Haenszel method). The risk difference (95 % CI) for achieving tpCR between the groups was within the pre-defined equivalence boundaries, demonstrating equivalent efficacy of BCD-178 and RP. The treatment groups were comparable in terms of safety profile, including the incidence of adverse reactions (ARs). The most common (≥10 % of patients) ARs were diarrhea and anemia. The pharmacokinetics and immunogenicity of the drugs were comparable.Conclusions. The study demonstrated comparability between BCD-178 and RP in terms of efficacy, safety, pharmacokinetics, and immunogenicity when used in the neoadjuvant treatment of patients with HER2-positive ER/PR-negative breast cancer.
- Open Access
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 9-17
Avelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study
Background: Immunotherapy-based regimens, such as nivolumab plus ipilimumab (Nivo-Ipi) and avelumab plus axitinib (Ave-Axi), are standard first-line treatments for metastatic clear-cell renal cell carcinoma (mRCC) with intermediate or poor IMDC risk. Comparative real-world evidence for these regimens remains limited.Methods: This retrospective cohort study included 102 patients with mRCC treated with Nivo-Ipi (n = 51) or AveAxi (n = 51) from 2018 to 2023. Propensity score matching was used to balance baseline characteristics, including IMDC risk and comorbidities. Primary endpoints were the rate of treatment-related adverse events (TRAEs) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and overall survival (OS).Results: Patient characteristics were balanced across cohorts, with a median age of 63.4 years, 76 % male, and 61 % having chronic cardiovascular diseases. The rate of any grade TRAEs was similar between Nivo-Ipi and Ave-Axi (62.7 % vs. 68.6 %, respectively), as was the rate of grade ≥ 3 TRAEs (11.7 % vs. 17.6 %). Patients treated with Ave-Axi had a significantly extended PFS (15.0 vs 9.7 months; p 0,05). The median OS was not reached.Conclusions: Nivo-Ipi and Ave-Axi are effective and well-tolerated first-line therapies for mRCC in real-world settings. Ave-Axi was associated with a significantly longer PFS and a numerically higher ORR compared to Nivo-Ipi.
- 22 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 9-17
Open AccessAvelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study
Background: Immunotherapy-based regimens, such as nivolumab plus ipilimumab (Nivo-Ipi) and avelumab plus axitinib (Ave-Axi), are standard first-line treatments for metastatic clear-cell renal cell carcinoma (mRCC) with intermediate or poor IMDC risk. Comparative real-world evidence for these regimens remains limited.Methods: This retrospective cohort study included 102 patients with mRCC treated with Nivo-Ipi (n = 51) or AveAxi (n = 51) from 2018 to 2023. Propensity score matching was used to balance baseline characteristics, including IMDC risk and comorbidities. Primary endpoints were the rate of treatment-related adverse events (TRAEs) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and overall survival (OS).Results: Patient characteristics were balanced across cohorts, with a median age of 63.4 years, 76 % male, and 61 % having chronic cardiovascular diseases. The rate of any grade TRAEs was similar between Nivo-Ipi and Ave-Axi (62.7 % vs. 68.6 %, respectively), as was the rate of grade ≥ 3 TRAEs (11.7 % vs. 17.6 %). Patients treated with Ave-Axi had a significantly extended PFS (15.0 vs 9.7 months; p 0,05). The median OS was not reached.Conclusions: Nivo-Ipi and Ave-Axi are effective and well-tolerated first-line therapies for mRCC in real-world settings. Ave-Axi was associated with a significantly longer PFS and a numerically higher ORR compared to Nivo-Ipi.
- 30 June 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 68 (2)
ENDOCRINE TOXICITY OF IMMUNE CHECKPOINT INHIBITORS IN CLINICAL PRACTICE
Relevance: Immunological control points significantly changed cancer therapy worldwide after a new class of inhibitor drugs was registered. Based on clinical studies, this type of treatment was associated with better survival in sensitive patients than cytostatic therapy. Checkpoint inhibitors exert their effect by regulating the immune response to malignant cells, blocking the usual inhibitory pathways of T-cell regulation. The receptors of cytotoxic T-lymphocytic antigen-4 (CTLA-4) and programmed cell death protein (PD-1) or its associated ligand (PD-L-1) are the target of inhibitors. CTLA-4 acts at an early stage of triggering an antigenic response, and PD-1 and PD-L-1 act by modulating interaction with peripheral tissue However, treatment with checkpoint inhibitors (ICTs) is accompanied by a wide range of immune mediated adverse events associated with the activation of the immune system. Despite the positive effect on survival, side effects with endocrine effects were noted in about 10% of patients. The study aimed to assess the incidence of immune mediated adverse events from the thyroid gland in clinical practice in patients with different localization of malignant tumors in the first and subsequent lines of therapy with checkpoint inhibitors. Methods: The study utilized anamnestic, laboratory, and instrumental tests. Laboratory analysis included determining the blood levels of TSH, T3, T4, ACTH, and cortisol. Data analysis was carried out using the Microsoft Excel program. Results: The frequency of development of immune mediated thyroiditis against the background of therapy with blockers of control points of the immune pathway in our observation was 29%. The debut of thyroid disorders was diagnosed in the first 12-16 weeks of therapy, beginning with hyperthyroidism against the background of thyroid destruction, followed by a transition to persistent hypothyroidism after 1-3 months. Conclusion: When analyzing the safety profile of ICTs in patients in our study, immune mediated adverse reactions did not differ in frequency and spectrum from world practice. The spectrum of toxicity did not depend on the localization of the tumor. Early diagnosis of thyroid lesions necessary for optimal and effective treatment can be carried out using laboratory tests. Knowing the timing of the development of adverse events during ICT therapy allows timely diagnosing and correcting complications from the thyroid to continue effective therapy.
- 30 June 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 68 (2)
ENDOCRINE TOXICITY OF IMMUNE CHECKPOINT INHIBITORS IN CLINICAL PRACTICE
Relevance: Immunological control points significantly changed cancer therapy worldwide after a new class of inhibitor drugs was registered. Based on clinical studies, this type of treatment was associated with better survival in sensitive patients than cytostatic therapy. Checkpoint inhibitors exert their effect by regulating the immune response to malignant cells, blocking the usual inhibitory pathways of T-cell regulation. The receptors of cytotoxic T-lymphocytic antigen-4 (CTLA-4) and programmed cell death protein (PD-1) or its associated ligand (PD-L-1) are the target of inhibitors. CTLA-4 acts at an early stage of triggering an antigenic response, and PD-1 and PD-L-1 act by modulating interaction with peripheral tissue However, treatment with checkpoint inhibitors (ICTs) is accompanied by a wide range of immune mediated adverse events associated with the activation of the immune system. Despite the positive effect on survival, side effects with endocrine effects were noted in about 10% of patients. The study aimed to assess the incidence of immune mediated adverse events from the thyroid gland in clinical practice in patients with different localization of malignant tumors in the first and subsequent lines of therapy with checkpoint inhibitors. Methods: The study utilized anamnestic, laboratory, and instrumental tests. Laboratory analysis included determining the blood levels of TSH, T3, T4, ACTH, and cortisol. Data analysis was carried out using the Microsoft Excel program. Results: The frequency of development of immune mediated thyroiditis against the background of therapy with blockers of control points of the immune pathway in our observation was 29%. The debut of thyroid disorders was diagnosed in the first 12-16 weeks of therapy, beginning with hyperthyroidism against the background of thyroid destruction, followed by a transition to persistent hypothyroidism after 1-3 months. Conclusion: When analyzing the safety profile of ICTs in patients in our study, immune mediated adverse reactions did not differ in frequency and spectrum from world practice. The spectrum of toxicity did not depend on the localization of the tumor. Early diagnosis of thyroid lesions necessary for optimal and effective treatment can be carried out using laboratory tests. Knowing the timing of the development of adverse events during ICT therapy allows timely diagnosing and correcting complications from the thyroid to continue effective therapy.
- 29 June 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 68 (2)
ENDOCRINE TOXICITY OF IMMUNE CHECKPOINT INHIBITORS IN CLINICAL PRACTICE
Relevance: Immunological control points significantly changed cancer therapy worldwide after a new class of inhibitor drugs was registered. Based on clinical studies, this type of treatment was associated with better survival in sensitive patients than cytostatic therapy. Checkpoint inhibitors exert their effect by regulating the immune response to malignant cells, blocking the usual inhibitory pathways of T-cell regulation. The receptors of cytotoxic T-lymphocytic antigen-4 (CTLA-4) and programmed cell death protein (PD-1) or its associated ligand (PD-L-1) are the target of inhibitors. CTLA-4 acts at an early stage of triggering an antigenic response, and PD-1 and PD-L-1 act by modulating interaction with peripheral tissue However, treatment with checkpoint inhibitors (ICTs) is accompanied by a wide range of immune mediated adverse events associated with the activation of the immune system. Despite the positive effect on survival, side effects with endocrine effects were noted in about 10% of patients. The study aimed to assess the incidence of immune mediated adverse events from the thyroid gland in clinical practice in patients with different localization of malignant tumors in the first and subsequent lines of therapy with checkpoint inhibitors. Methods: The study utilized anamnestic, laboratory, and instrumental tests. Laboratory analysis included determining the blood levels of TSH, T3, T4, ACTH, and cortisol. Data analysis was carried out using the Microsoft Excel program. Results: The frequency of development of immune mediated thyroiditis against the background of therapy with blockers of control points of the immune pathway in our observation was 29%. The debut of thyroid disorders was diagnosed in the first 12-16 weeks of therapy, beginning with hyperthyroidism against the background of thyroid destruction, followed by a transition to persistent hypothyroidism after 1-3 months. Conclusion: When analyzing the safety profile of ICTs in patients in our study, immune mediated adverse reactions did not differ in frequency and spectrum from world practice. The spectrum of toxicity did not depend on the localization of the tumor. Early diagnosis of thyroid lesions necessary for optimal and effective treatment can be carried out using laboratory tests. Knowing the timing of the development of adverse events during ICT therapy allows timely diagnosing and correcting complications from the thyroid to continue effective therapy.
- 29 June 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 68 (2)
ENDOCRINE TOXICITY OF IMMUNE CHECKPOINT INHIBITORS IN CLINICAL PRACTICE
Relevance: Immunological control points significantly changed cancer therapy worldwide after a new class of inhibitor drugs was registered. Based on clinical studies, this type of treatment was associated with better survival in sensitive patients than cytostatic therapy. Checkpoint inhibitors exert their effect by regulating the immune response to malignant cells, blocking the usual inhibitory pathways of T-cell regulation. The receptors of cytotoxic T-lymphocytic antigen-4 (CTLA-4) and programmed cell death protein (PD-1) or its associated ligand (PD-L-1) are the target of inhibitors. CTLA-4 acts at an early stage of triggering an antigenic response, and PD-1 and PD-L-1 act by modulating interaction with peripheral tissue However, treatment with checkpoint inhibitors (ICTs) is accompanied by a wide range of immune mediated adverse events associated with the activation of the immune system. Despite the positive effect on survival, side effects with endocrine effects were noted in about 10% of patients. The study aimed to assess the incidence of immune mediated adverse events from the thyroid gland in clinical practice in patients with different localization of malignant tumors in the first and subsequent lines of therapy with checkpoint inhibitors. Methods: The study utilized anamnestic, laboratory, and instrumental tests. Laboratory analysis included determining the blood levels of TSH, T3, T4, ACTH, and cortisol. Data analysis was carried out using the Microsoft Excel program. Results: The frequency of development of immune mediated thyroiditis against the background of therapy with blockers of control points of the immune pathway in our observation was 29%. The debut of thyroid disorders was diagnosed in the first 12-16 weeks of therapy, beginning with hyperthyroidism against the background of thyroid destruction, followed by a transition to persistent hypothyroidism after 1-3 months. Conclusion: When analyzing the safety profile of ICTs in patients in our study, immune mediated adverse reactions did not differ in frequency and spectrum from world practice. The spectrum of toxicity did not depend on the localization of the tumor. Early diagnosis of thyroid lesions necessary for optimal and effective treatment can be carried out using laboratory tests. Knowing the timing of the development of adverse events during ICT therapy allows timely diagnosing and correcting complications from the thyroid to continue effective therapy.